Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia - PubMed (original) (raw)
. 2010 Nov 25;116(22):4631-8.
doi: 10.1182/blood-2010-05-282426. Epub 2010 Aug 20.
Tsutomu Toki, Kiminori Terui, Gang Xu, Runan Wang, Akira Shimada, Asahito Hama, Hirokazu Kanegane, Kiyoshi Kawakami, Mikiya Endo, Daisuke Hasegawa, Kazuhiro Kogawa, Souichi Adachi, Yasuhiko Ikeda, Shotaro Iwamoto, Takashi Taga, Yoshiyuki Kosaka, Seiji Kojima, Yasuhide Hayashi, Etsuro Ito
Affiliations
- PMID: 20729467
- DOI: 10.1182/blood-2010-05-282426
Free article
Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia
Rika Kanezaki et al. Blood. 2010.
Free article
Abstract
Twenty percent to 30% of transient abnormal myelopoiesis (TAM) observed in newborns with Down syndrome (DS) develop myeloid leukemia of DS (ML-DS). Most cases of TAM carry somatic GATA1 mutations resulting in the exclusive expression of a truncated protein (GATA1s). However, there are no reports on the expression levels of GATA1s in TAM blasts, and the risk factors for the progression to ML-DS are unidentified. To test whether the spectrum of transcripts derived from the mutant GATA1 genes affects the expression levels, we classified the mutations according to the types of transcripts, and investigated the modalities of expression by in vitro transfection experiments using GATA1 expression constructs harboring mutations. We show here that the mutations affected the amount of mutant protein. Based on our estimates of GATA1s protein expression, the mutations were classified into GATA1s high and low groups. Phenotypic analyses of 66 TAM patients with GATA1 mutations revealed that GATA1s low mutations were significantly associated with a risk of progression to ML-DS (P < .001) and lower white blood cell counts (P = .004). Our study indicates that quantitative differences in mutant protein levels have significant effects on the phenotype of TAM and warrants further investigation in a prospective study.
Similar articles
- Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P; International Myeloid Leukemia-Down Syndrome Study Group. Alford KA, et al. Blood. 2011 Aug 25;118(8):2222-38. doi: 10.1182/blood-2011-03-342774. Epub 2011 Jun 29. Blood. 2011. PMID: 21715302 - GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH, Choong SS, Krishnan S, Mohamed Z, Ariffin H. Lum SH, et al. Singapore Med J. 2016 Jun;57(6):320-4. doi: 10.11622/smedj.2016106. Singapore Med J. 2016. PMID: 27353457 Free PMC article. - GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C, Cruz Hernandez D, Vyas P. Garnett C, et al. IUBMB Life. 2020 Jan;72(1):119-130. doi: 10.1002/iub.2197. Epub 2019 Nov 26. IUBMB Life. 2020. PMID: 31769932 Review. - Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21.
Barwe SP, Sebastian A, Sidhu I, Kolb EA, Gopalakrishnapillai A. Barwe SP, et al. Cells. 2022 Feb 11;11(4):628. doi: 10.3390/cells11040628. Cells. 2022. PMID: 35203280 Free PMC article. - Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K. Watanabe K. Pediatr Int. 2019 Mar;61(3):222-229. doi: 10.1111/ped.13776. Epub 2019 Mar 4. Pediatr Int. 2019. PMID: 30593694 Review.
Cited by
- Down syndrome-associated leukaemias: current evidence and challenges.
Mason NR, Cahill H, Diamond Y, McCleary K, Kotecha RS, Marshall GM, Mateos MK. Mason NR, et al. Ther Adv Hematol. 2024 Jul 23;15:20406207241257901. doi: 10.1177/20406207241257901. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39050114 Free PMC article. Review. - Cytokine profiling in 128 patients with transient abnormal myelopoiesis: a report from the JPLSG TAM-10 trial.
Yamato G, Tsumura Y, Muramatsu H, Shimada A, Imaizumi T, Tsukagoshi H, Kaburagi T, Shiba N, Yamada Y, Deguchi T, Kawai T, Terui K, Ito E, Watanabe K, Hayashi Y. Yamato G, et al. Blood Adv. 2024 Jun 25;8(12):3120-3129. doi: 10.1182/bloodadvances.2023011628. Blood Adv. 2024. PMID: 38691583 Free PMC article. Clinical Trial. - The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice.
Ishihara D, Hasegawa A, Hirano I, Engel JD, Yamamoto M, Shimizu R. Ishihara D, et al. Exp Hematol Oncol. 2024 Feb 26;13(1):24. doi: 10.1186/s40164-024-00492-9. Exp Hematol Oncol. 2024. PMID: 38409186 Free PMC article. - Prenatal diagnosis of Down syndrome combined with transient abnormal myelopoiesis in foetuses with a GATA1 gene variant: two case reports.
Tang H, Hu J, Liu L, Lv L, Lu J, Yang J, Lu J, Chen Z, Yang C, Chen D, Fu J, Wu J. Tang H, et al. Mol Cytogenet. 2023 Oct 19;16(1):27. doi: 10.1186/s13039-023-00658-w. Mol Cytogenet. 2023. PMID: 37858167 Free PMC article. - Bullous eruptions in transient abnormal myelopoiesis with normal phenotype.
Shivamallappa MD, Mullins A, Browning Carmo K. Shivamallappa MD, et al. BMJ Case Rep. 2023 Apr 7;16(4):e251523. doi: 10.1136/bcr-2022-251523. BMJ Case Rep. 2023. PMID: 37028822
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical